Stable Cannabinoid Formulations with Purification and Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Commercially available cannabidiol products are often contaminated with delta-9-tetrahydrocannabinol, a Schedule I drug, making them difficult to access and posing undesirable psychoactive side effects, while there is a need for stable, pure cannabidiol formulations for treating various diseases and disorders.
Innovation Solution
Development of substantially pure, synthetically synthesized cannabidiol formulations using vehicles like medium chain glycerides and sesame oil, with antioxidants and preservatives, for oral administration, ensuring high purity and stability, and avoiding delta-9-tetrahydrocannabinol contamination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercially available cannabidiol is used, then treatment availability is improved, but purity is worsened due to delta-9-tetrahydrocannabinol contamination
Solution Approach 1:
The patent extracts and removes delta-9-tetrahydrocannabinol contaminant from cannabidiol formulations through purification processes, isolating the desired cannabidiol compound while eliminating the harmful Schedule I drug component, thereby achieving high purity (>98%) cannabidiol formulations
Solution Approach 2:
The patent changes the chemical composition parameters by establishing specific purity thresholds (>98% cannabidiol, <0.3% delta-9-tetrahydrocannabinol) and using synthetic production methods with controlled reaction conditions to achieve precise compositional control, resolving the purity problem while maintaining availability
2Ease of manufacture
If delta-9-tetrahydrocannabinol is present in cannabidiol formulations, then commercial availability is improved, but harmful effects are worsened due to psychoactive side effects and Schedule I drug status
Solution Approach 1:
The patent converts the harmful presence of delta-9-tetrahydrocannabinol contaminant into a benefit by establishing strict purification protocols that eliminate the harmful psychoactive effects while preserving the therapeutic benefits of cannabidiol, transforming an unavailable pure formulation into an accessible safe formulation
Solution Approach 2:
The patent removes the harmful delta-9-tetrahydrocannabinol component from the formulation through extraction and purification processes, eliminating the source of psychoactive side effects and Schedule I drug status while maintaining cannabidiol therapeutic availability
3Stability of the object's composition
If cannabidiol formulations are stabilized with antioxidants and preservatives, then stability is improved, but device complexity is worsened
Solution Approach 1:
The patent introduces antioxidants (such as vitamin E) and preservatives as intermediary substances that mediate between the cannabidiol active ingredient and environmental degradation factors (oxidation, microbial contamination), protecting the formulation stability without significantly complicating the overall product structure
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining cannabidiol with stabilizing agents (antioxidants, preservatives) and delivery vehicles (oils, emulsifiers) in specific ratios, achieving enhanced stability through material composition rather than complex processing or delivery systems
Data Source
AI summary
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.